Evidence map›Paper›PMID 35169588›Full record

ArticleOpen forum infectious diseases2022

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.

Kaitlyn M Vette, Dorothy A Machalek, Heather F Gidding, Suellen Nicholson, Matthew V N O'Sullivan, John B Carlin, Marnie Downes, Lucy Armstrong, Frank H Beard, Dominic E Dwyer and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kaitlyn M VetteNational Centre for Immunisation Research and Surveillance, Sydney, Australia.ORCID https://orcid.org/0000-0001-7720-1431
Dorothy A MachalekThe Kirby Institute, University of New South Wales, Sydney, Australia.
Heather F GiddingNational Centre for Immunisation Research and Surveillance, Sydney, Australia.
Suellen NicholsonVictorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Matthew V N O'SullivanCentre for Infectious Diseases and Microbiology, New South Wales Health Pathology - Institute for Clinical Pathology and Medical Research, Sydney, Australia.
John B CarlinMurdoch Children's Research Institute, Melbourne, Australia.
Marnie DownesMurdoch Children's Research Institute, Melbourne, Australia.ORCID https://orcid.org/0000-0002-0677-2517
Lucy ArmstrongNational Centre for Immunisation Research and Surveillance, Sydney, Australia.
Frank H BeardNational Centre for Immunisation Research and Surveillance, Sydney, Australia.
Dominic E DwyerCentre for Infectious Diseases and Microbiology, New South Wales Health Pathology - Institute for Clinical Pathology and Medical Research, Sydney, Australia.
Robert GibbPathology Queensland, Brisbane, Australia.
Iain B GosbellClinical Services and Research, Australian Red Cross Lifeblood, Sydney, Australia.
Alexandra J HendryNational Centre for Immunisation Research and Surveillance, Sydney, Australia.
Geoff HigginsSouth Australia Pathology, Adelaide, Australia.
Rena HiraniClinical Services and Research, Australian Red Cross Lifeblood, Sydney, Australia.
Linda HuestonCentre for Infectious Diseases and Microbiology, New South Wales Health Pathology - Institute for Clinical Pathology and Medical Research, Sydney, Australia.
David O IrvingClinical Services and Research, Australian Red Cross Lifeblood, Sydney, Australia.
Helen E QuinnNational Centre for Immunisation Research and Surveillance, Sydney, Australia.
Hannah ShillingCentre for Women's Infectious Diseases, The Royal Women's Hospital Melbourne, Melbourne, Australia.
David SmithPathWest Laboratory Medicine Western Australia, Perth, Australia.
John M KaldorThe Kirby Institute, University of New South Wales, Sydney, Australia.
Kristine MacartneyNational Centre for Immunisation Research and Surveillance, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs of mid-2021, Australia's only nationwide coronavirus disease 2019 (COVID-19) epidemic occurred in the first 6 months of the pandemic. Subsequently, there has been limited transmission in most states and territories. Understanding community spread during the first wave was hampered by initial limitations on testing and surveillance. To characterize the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody seroprevalence generated during this time, we undertook Australia's largest national SARS-CoV-2 serosurvey.

methodsBetween June 19 and August 6, 2020, residual specimens were sampled from people undergoing general pathology testing (all ages), women attending antenatal screening (20-39 years), and blood donors (20-69 years) based on the Australian population's age and geographic distributions. Specimens were tested by Wantai total SARS-CoV-2-antibody assay. Seroprevalence estimates adjusted for test performance were produced. The SARS-CoV-2 antibody-positive specimens were characterized with microneutralization assays.

resultsOf 11 317 specimens (5132 general pathology; 2972 antenatal; 3213 blood-donors), 71 were positive for SARS-CoV-2-specific antibodies. Seroprevalence estimates were 0.47% (95% credible interval [CrI], 0.04%-0.89%), 0.25% (CrI, 0.03%-0.54%), and 0.23% (CrI, 0.04%-0.54%), respectively. No seropositive specimens had neutralizing antibodies.

conclusionsAustralia's seroprevalence was extremely low (<0.5%) after the only national COVID-19 wave thus far. These data and the subsequent limited community transmission highlight the population's naivety to SARS-CoV-2 and the urgency of increasing vaccine-derived protection.

Indexed as

AustraliaCOVID-19SARS-CoV-2seroprevalenceserosurvey

Identifiers

PMID35169588
PMCPMC8842318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.